Specific removal of antiacetylcholine receptor antibodies in patients with myasthenia gravis

Transfusion Science

Volumn 17, Issue 3, 1996, Pages 445-453

  Takamori, Masaharu ^a   Ide, Yoshihiko ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; ANTIBODY; CHOLINERGIC RECEPTOR;

FILTRATION; HUMAN; IMMUNOADSORBENT; IMMUNOADSORPTION; MYASTHENIA GRAVIS; PLASMAPHERESIS; PURIFICATION; REVIEW; SKELETAL MUSCLE; THROMBOSIS; TREATMENT OUTCOME; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION;

ANTIBODIES; HUMANS; IMMUNOSORBENT TECHNIQUES; IMMUNOSORBENTS; MYASTHENIA GRAVIS; RECEPTORS, CHOLINERGIC;

EID: 0345879074     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/0955-3886(96)00028-8     Document Type: Article

References (25)

1. Drachman DB: Myasthenia gravis. N Engl J Med 1994; 330:1797-1810.
2. Yamazaki A, Fujimori Y, Takahama T, et al.: Efficiency and biocompatibility of a new immunoadsorbent. Trans Am Soc Artif Intern Organs 1982; 28:318-323.
3. Sato T, Nishimiya J, Arai K, et al.: Selective removal of anti-acetylcholine receptor antibody in sera from patients with myasthenia gravis in vitro with a new immunoadsorbent. Ther Plasmapheresis 1983; 3:565-568.
4. Numa S, Noda M, Takahashi T, et al.: Molecular structure of the nicotinic acetylcholine receptor. Cold Spring Harbor Symp Quant Biol 1983; 48:57-70.
5. Ratnum M, Le Nguyen D, Rivier J, et al.: Transmembrane topography of nicotinic acetylcholine receptor: Immunochemical tests contradict theoretical predictions based on hydrophobicity profiles. Biochemistry 1986; 25:2633-2643.
6. Tzartos SJ, Barkas T, Cung MT, et al.: The main immunogenic region of the acetylcholine receptor. Structure and role in myasthenia gravis. Autoimmunity 1991; 8:256-270.
7. Manfredi AA, Protti MP, Bellone M, et al.: Molecular anatomy of an autoantigen: T and B epitopes on the nicotinic acetylcholine receptor in myasthenia gravis. J Lab Clin Med 1992; 120:13-21.
8. Takamori M, Okumura S, Nagata M, et al.: Myasthenogenic significance of synthetic α-subunit peptide 183-200 of Torpedo californica and human acetylcholine receptor. J Neurol Sci 1988; 85:121-129.
9. Somnier FE, Langvad E: Plasma exchange with selective immunoadsorption of anti-acetylcholine receptor antibodies. J Neuroimmunol 1989; 22:123-127.
10. Pinching AJ, Peters DK: Remission of myasthenia gravis following plasmaexchange. Lancet 1976; 2:1373-1376.
11. Behan PO, Shakir RA, Simpson JA, et al.: Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. Lancet 1979; 2:438-440.
12. Milner-Brown HS, Miller RG: Time course of improved neuromuscular function following plasma exchange alone and plasma exchange with prednisolone/ azathioprine in myasthenia gravis. J Neurol Sci 1982; 57:357-368.
13. Fornadi L, Horvath R, Szobor A: Myasthenia gravis: treatment with plasma exchange experiences over 10 years. Acta Med Hung 1991; 48:137-144.
14. d'Empaire G, Hoaglin DC, Perlo VP, et al.: Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis. J Thorac Cardiovasc Surg 1985; 89:592-596.
15. Campbell W Jr, Leshner RT, Swift TR: Plasma exchange in myasthenia gravis: Electrophysiological studies. Ann Neurol 1980; 8:584-589.
16. Nielsen VK, Paulson OB, Rosenkvist J, et al.: Rapid improvement of myasthenia gravis after plasma exchange. Ann Neurol 1982; 11:160-169.
17. Stricker RB, Kwiatkowska BJ, Habis JA, et al.: Myasthenic crisis. Response to plasmapheresis following failure of intravenous gamma-globulin. Arch Neurol 1993; 50:837-840.
18. Shibuya N, Sato T, Osame M, et al.: Immunoadsorption therapy for myasthenia gravis. J Neurol Neurosurg Psychiatry 1994; 57:578-581.
19. Grob D, Simpson D, Mitsumoto H, et al.: Treatment of myasthenia gravis by immunoadsorption of plasma. Neurology 1995; 45:338-344.
20. Takamori M, Okumura S, Ide Y: A synthetic peptide, Torpedo californica α183-200, of the acetylcholine receptor as a tool for immunoadsorption via plasma perfusion in myasthenia gravis. Artif Organs Today 1991; 1:53-60.
21. Takamori M, Okumura S, Komai K, et al.: Conformational modification enhances myasthenogenicity in synthetic peptide of acetylcholine receptor α-subunit. J Neurol Sci 1990; 99:219-227.
22. Takamori M, Hamada T, Okumura S: Myasthenogenicity in the main immunogenic region of acetylcholine receptor as modified by conformational design: an approach to antigenic synthetic peptides. J Neurol Sci 1992; 109: 182-187.
23. McLeod BC, Viernes A, Sassetti RJ: Complement metabolism during membrane plasma separation. Artif Organs 1983; 7:443-449.
24. Weigle WO, Goodman MG, Morgan EL, et al.: Regulation of immune response by components of the complement cascade and their activated fragments. Springer Semin Immunopathol 1983; 6:173-194.
25. Couriel D, Weinstein R: Complications of therapeutic plasma exchange: a recent assessment. J Clin Apheresis 1994; 9:1-5.